Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focusing on rare disease treatments, has announced its participation in several upcoming investor and scientific conferences. The company will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, the 6th Annual Exosome-Based Therapeutic Summit from September 17-19, 2024, and the 2024 Cantor Fitzgerald's Global Healthcare Conference on September 18, 2024.
During these events, Capricor management will provide updates on the company's progress, particularly regarding its lead program, deramiocel for Duchenne muscular dystrophy (DMD) treatment. The presentations will include company overviews, one-on-one meetings, and participation in industry panels, offering investors and industry professionals insights into Capricor's latest developments in cell and exosome-based therapeutics.
Capricor Therapeutics (NASDAQ: CAPR), una società di biotecnologie focalizzata sui trattamenti per malattie rare, ha annunciato la sua partecipazione a diversi prossimi conferenze per investitori e scientifiche. L'azienda presenterà alla 26a Conferenza Globale Annuale sugli Investimenti H.C. Wainwright il 9 settembre 2024, al 6° Summit Annuale sulle Terapie Basate su Esozomi dal 17 al 19 settembre 2024, e alla Conferenza Sanitaria Globale 2024 di Cantor Fitzgerald il 18 settembre 2024.
Durante questi eventi, il management di Capricor fornirà aggiornamenti sui progressi dell'azienda, in particolare riguardo al suo programma principale, deramiocel per il trattamento della distrofia muscolare di Duchenne (DMD). Le presentazioni includeranno panoramiche aziendali, incontri individuali e partecipazione a pannelli del settore, offrendo agli investitori e ai professionisti dell'industria approfondimenti sugli ultimi sviluppi di Capricor nelle terapie basate su cellule ed esoziomi.
Capricor Therapeutics (NASDAQ: CAPR), una compañía de biotecnología centrada en tratamientos para enfermedades raras, ha anunciado su participación en varias conferencias científicas y de inversores próximas. La empresa presentará en la 26ª Conferencia Global Anual de Inversiones H.C. Wainwright el 9 de septiembre de 2024, en el 6º Summit Anual sobre Terapias Basadas en Exosomas del 17 al 19 de septiembre de 2024, y en la Conferencia Global de Salud 2024 de Cantor Fitzgerald el 18 de septiembre de 2024.
Durante estos eventos, la dirección de Capricor proporcionará actualizaciones sobre el progreso de la empresa, particularmente en relación con su programa principal, deramiocel para el tratamiento de la distrofia muscular de Duchenne (DMD). Las presentaciones incluirán vistas generales de la compañía, reuniones uno a uno y participación en paneles de la industria, brindando a inversores y profesionales del sector información sobre los últimos desarrollos de Capricor en terapias basadas en células y exosomas.
Capricor Therapeutics (NASDAQ: CAPR), 희귀 질환 치료에 중점을 둔 생명공학 회사가 다가오는 여러 투자자 및 과학 컨퍼런스에 참여한다고 발표했습니다. 회사는 2024년 9월 9일에 있을 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스, 2024년 9월 17일부터 19일까지 열리는 제6회 엑소좀 기반 치료 정상 회담, 2024년 9월 18일에 개최되는 Cantor Fitzgerald의 2024 글로벌 헬스케어 컨퍼런스에 참석할 예정입니다.
이 행사 동안 Capricor 경영진은 회사의 발전 상황, 특히 Duchenne 근이영양증(DMD) 치료를 위한 deramiocel의 주요 프로그램에 대한 업데이트를 제공할 것입니다. 발표에는 회사 개요, 일대일 회의 및 업계 패널 참여가 포함되어, 투자자 및 업계 전문가에게 Capricor의 최신 세포 및 엑소좀 기반 치료 개발에 대한 통찰력을 제공할 것입니다.
Capricor Therapeutics (NASDAQ: CAPR), une entreprise de biotechnologie axée sur les traitements des maladies rares, a annoncé sa participation à plusieurs conférences scientifiques et pour investisseurs à venir. L'entreprise présentera à la 26e Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright le 9 septembre 2024, au 6e Sommet Annuel sur les Thérapies Basées sur les Exosomes du 17 au 19 septembre 2024, et à la Conférence Mondiale sur la Santé 2024 de Cantor Fitzgerald le 18 septembre 2024.
Lors de ces événements, la direction de Capricor fournira des mises à jour sur les progrès de l'entreprise, en particulier concernant son programme principal, deramiocel pour le traitement de la dystrophie musculaire de Duchenne (DMD). Les présentations comprendront des aperçus de l'entreprise, des réunions individuelles et la participation à des panels de l'industrie, offrant aux investisseurs et aux professionnels du secteur des aperçus sur les derniers développements de Capricor dans les thérapies basées sur les cellules et les exosomes.
Capricor Therapeutics (NASDAQ: CAPR), ein Biotechnologieunternehmen, das sich auf die Behandlung seltener Krankheiten konzentriert, hat seine Teilnahme an mehreren bevorstehenden Investoren- und Wissenschaftskonferenzen angekündigt. Das Unternehmen wird am 9. September 2024 auf der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright, vom 17. bis 19. September 2024 auf dem 6. jährlichen Exosom-basierten Therapiegipfel und am 18. September 2024 auf der Global Healthcare Conference 2024 von Cantor Fitzgerald präsentieren.
Während dieser Veranstaltungen wird das Management von Capricor Updates über die Fortschritte des Unternehmens geben, insbesondere in Bezug auf sein Hauptprogramm, deramiocel zur Behandlung der Duchenne-Muskeldystrophie (DMD). Die Präsentationen umfassen Unternehmensübersichten, Einzelgespräche und die Teilnahme an Branchendiskussionen, die Investoren und Branchenprofis Einblicke in die neuesten Entwicklungen von Capricor im Bereich der Zell- und exosom-basierten Therapeutika bieten.
- None.
- None.
SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to present at various upcoming investor and scientific conferences.
| Event: | H.C. Wainwright 26th Annual Global Investment Conference (New York, NY) |
| Presentation: | September 9, 2024 at 2:00 p.m. ET |
| Format: | Company presentation and one-on-one meetings |
| Event: | 6th Annual Exosome-Based Therapeutic Summit (Boston, MA) |
| Presentation: | September 17-19, 2024 |
| Format: | Company presentation and industry panel |
Event: | 2024 Cantor Fitzgerald’s Global Healthcare Conference (New York, NY) |
| Presentation: | September 18, 2024 at 8:35 a.m. ET |
| Format: | Fireside chat and one-on-one meetings |
Capricor management will present updates on Capricor’s recent progress on its lead program of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) as well as other general scientific and corporate updates. For more information on these presentations, please visit Capricor's website at http://capricor.com/news/events/.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, deramiocel (CAP-1002), an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown deramiocel to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and Twitter.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; statements about our financial outlook; the ability to achieve product milestones and to receive milestone payments from commercial partners; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future revenue streams and projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on March 11, 2024, and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, as filed with the Securities and Exchange Commission on August 8, 2024. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
Capricor has entered into an agreement for the exclusive commercialization and distribution of deramiocel (CAP-1002) for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. Deramiocel is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation.
For more information, please contact:
Capricor Media Contact:
Raquel Cona
KCSA Strategic Communications
rcona@kcsa.com
212.896.1204
Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755
FAQ
What conferences will Capricor Therapeutics (CAPR) attend in September 2024?
What is Capricor Therapeutics' (CAPR) lead program?
When will Capricor Therapeutics (CAPR) present at the H.C. Wainwright conference?
What type of therapeutics does Capricor Therapeutics (CAPR) develop?
